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ErythrophagocytosisHeme serves as a co-factor in proteins involved in fundamental biological processes including oxidative
metabolism, oxygen storage and transport, signal transduction and drug metabolism. In addition, heme is
important for systemic iron homeostasis inmammals. Heme has important regulatory roles in cell biology, yet
excessive levels of intracellular heme are toxic; thus, mechanisms have evolved to control the acquisition,
synthesis, catabolism and expulsion of cellular heme. Recently, a number of transporters of heme and heme
synthesis intermediates have been described. Here we review aspects of heme metabolism and discuss our
current understanding of heme transporters, with emphasis on the function of the cell-surface heme exporter,
FLVCR. Knockdown of Flvcr in mice leads to both defective erythropoiesis and disturbed systemic iron
homeostasis, underscoring the critical role of heme transporters in mammalian physiology.niversity of Illinois College of
, USA. Tel.: +1 312 413 1300.
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Porphyrins are heterocyclic organic rings composed of four pyrrole
subunits that are usually linked by methine bridges; their conjugation
to diverse divalent metal ions such as Mg2+, Co+ and Fe2+ gives rise to
the “pigments of life”, i.e., chlorophyll, vitamin B12 and heme,
respectively. Heme, a complex of iron with protoporphyrin IX, is
ubiquitous in aerobic cells and essential for cellular oxidation–reduction
reactions. It serves as a critical component of hemoproteins, a large
group of proteins that includes cytochromes (for mitochondrial
respiratory chain electron transfer and drug metabolism), oxidases
(e.g., NADPH oxidase) and peroxidases, catalases and synthases (e.g.,
nitric oxide synthase, NOS), as well as the oxygen storage and transport
molecules, myoglobin and hemoglobin (Hb) (for reviews see [1,2]). In
addition, two-thirds of Western dietary iron intake is derived from
dietary heme [3], while themajority of iron in the body is present in the
form of heme (as Hb, myoglobin and cytochromes [4]).
In single-cell organisms the primary importance of heme derives
from its role as a source of iron and as a critical component of enzymes of
the respiratory chain. Its regulated production and use appears to be
intimately related to the presence of oxygen, providing the cell with the
ability to exploit the beneﬁts of oxidativemetabolism [5,6]. Thus it is not
surprising that heme (likeMg2+-protoporphyrin in plants [7]) has itselfevolved to serve as a fundamental cell regulatorymolecule in single-cell
and more complex organisms. In mammals heme has pleiotropic
functions, but its underlying relationship to oxygen and oxidative
metabolism remains central. For example it is intimately involved in the
regulation of erythropoiesis, regulating erythroid gene transcription—
e.g., nuclear heme inhibits repression of the globin locus by the
transcription factor Bach1, likely through direct binding [8]; erythroid
gene translation, through inhibition of an erythroid-speciﬁc eIF-2α
kinase (HRI) that regulates protein, especially globin translation [9,10];
and heme synthesis protein targeting and stability [11,12]. Recently, the
role of heme in other fundamental cell processes – e.g., the regulation of
microRNA processing [13], circadian rhythm [14] and ion-channel
functions [15] – has been described. In addition, heme appears to
promote speciﬁc gene expression patterns in mammalian adipose,
neuronal and erythroid cells, inducing their differentiation [16–20].
Finally, in addition to its redox ability in electron transfer (e.g., the
respiratory chain hemoproteins), iron compartmentalization function
and aforementioned regulatory roles, heme also binds NO, CO and O2,
allowing hemoproteins to serve as gas sensors and signal transducers
[21,22].
The observations outlined above would seem to argue for a
physiological role for a “free” or “uncommitted” heme pool, i.e.,
intracellular heme that is not a component of hemoproteins.
However, free heme is lipophilic and toxic to cells, promoting lipid
peroxidation [2,23] and the production of reactive oxygen species
(ROS) [24], resulting in membrane injury and cell apoptosis [2].
Therefore, both from the viewpoint of its toxicity and its regulatory
function, the intracellular levels of free heme must be tightly
controlled (estimated at b0.1 μM; reviewed in [2,25]). Like zinc in
prokaryotes [26], “free heme” has been proposed to be chaperoned by
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include glutathione S-transferase B (ligandin, [28]), Z-type-fatty acid-
binding protein [29], heme-binding protein 22 (p22HBP, [30]) and
HBP23, [31], and, more recently, biliverdin reductase (BVR) [32].
However, the speciﬁc proteins responsible for the safe carriage of
heme within cells remain for the most part unidentiﬁed.
Control of intracellular heme levels was previously thought to
occur through a balance among its mitochondrial biosynthesis,
utilization by hemoproteins, and catabolism by heme oxygenases
(HO) (predominantly by the heme-inducible HO-1) [1]. However,
studies describing transporters of heme and heme synthesis inter-
mediates indicate further layers of complexity in heme homeostasis.
Being lipophilic, heme readily associates with cell and organelle
membranes; yet, the presence of anionic carboxylate side chains,
responsible for heme binding to heme carrier proteins, such as
albumin and hemopexin (Hpx), limits transmembrane diffusion [33],
indicating the need for speciﬁc transporters, as supported by a
number of studies [34–38] (see also [39,40] for recent reviews).
In recent years a number of these heme transport proteins have
been identiﬁed. The purpose of this review is to describe relevant
aspects of heme synthesis and catabolism and then outline our
current understanding of heme transporters. We discuss heme
transporters that function at different sites within the cell, with
emphasis on the role of the plasma membrane heme exporter FLVCR.
Table 1 summarizes our current knowledge of these transporters.Table 1
Transmembrane proteins implicated in the transport or biosynthesis of heme.
Protein Description Function Localizatio
FLVCR MFS transporter. FeLV-C viral
receptor. Virus cause anemia
in cats.
Exports heme (and PPIX).
Does not transport bilirubin.
Plasma
membran
ABCG2/BCRP ABC family member. Confers
multidrug resistance in
breast cancer cell line.
Potentially exports heme.
Exports (conjugated) PPIX,
pheophorbide A, urate.
Plasma
membran
ABCB6 ABC family member.
Functionally complements
yeast Atm1p mutant which
accumulates iron in
mitochondria.
Unknown, suggested may
transport mitochondrial
CPgen III.
Mitochon
OM, plasm
membran
endosome
lysosome.
ABCB10 ABC family member. GATA-1
regulated.
Transport substrate
unknown. Interacts with
Fech and Mfrn1. Stabilizes
Mfrn1 to allow increased
mitochondrial iron uptake
during erythropoiesis.
Mitochon
ABCB7 ABC family member. Human
ortholog of yeast Atm1p
which accumulates iron in
mitochondria.
Interacts with Fech. Cytosolic
Fe–S protein maturation,
iron homeostasis.
Mitochon
PCFT/HCP1 MFS transporter. Proton
coupled folate transporter/
Heme carrier protein isolated
from hypotransferrinemic
mouse duodenal tissue.
Primarily a folate
transporter. Physiological
role in duodenal heme
import unclear
Plasma
membran
Endosome
HRG-1 Transporter with 4 predicted
transmembrane domains.
Heme regulated gene in C.
elegans. Ortholog present in
humans.
Exports heme from
lysosome/endosome into
cytoplasm.
Endosome
Lysosome
HRG-4 Transporter with either 3 or
5 predicted transmembrane
domains. Heme regulated
gene in C. elegans, no
mammalian orthologs.
Imports heme. Plasma
membran2. Heme synthesis and transport of heme synthesis intermediates
The ﬁrst of eight steps in heme synthesis (Fig. 1; for comprehensive
reviews see [41–43]), mediated by the enzyme ALA synthase 2 (ALAS2)
in erythroid cells or by the heme-repressible enzyme ALAS1 in non-
erythroid cells, is the condensation of succinyl co-enzyme A and glycine
to form 5-amino-levulinic acid (ALA), which occurs within the
mitochondrial matrix. ALA is then transported across both mitochon-
drial inner and outermembranes (IM andOM) into the cytosol. Patients
with mutations of ALAS2 develop sideroblastic anemia, a hematological
disorder characterized by mitochondrial iron overload and impaired
heme synthesis [44], while accumulation of substrates related to defects
in the remaining pathway enzymes results in porphyrias, disorders
characterized by either acute neurovisceral attacks or photosensitivity
or sometimes both (reviews, [43,45]). Intriguingly, a recent study
identiﬁedmutations of the solute carrier SLC25A38, a mitochondrial IM
transporter, as a frequent cause of inherited sideroblastic anemia [46].
Deletion of the yeast ortholog decreases heme synthesis, which is
rescued by supplementing the culture media with glycine or ALA. Yeast
cytosolic levels of ALA were reduced 6.7-fold compared to controls,
leading the authors to propose that SLC25A38 functions to facilitate
ALA production by transporting glycine into the matrix or exchanging
glycine for ALA across the IM.
In the cytosol the cyclic tetrapyrrole, coproporphyrinogen III
(CPgenIII), is formed from ALA in a series of four enzymatic reactions.n Disorders Knockout Reference
e.
Diamond Blackfan
anemia? Posterior
column ataxia and
retinitis pigmentosa
Mouse KO is embryonic
lethal. Early erythroid
progenitor arrest and
systemic iron overload in
conditional KO.
[36,37,189]
e.
Increased serum urate
level, resulting in gout.
Mouse KO have 10-fold
elevated PPIX in RBCs and in
plasma. No hematologic
abnormality, no evidence of
iron overload.
[229,235,236,238]
drial
a
e, golgi,
/
Mouse KO generated by
Schuetz group
(unpublished).
[47,58]
drial IM. Mouse KO embryonic lethal.
Arrested erythroid
differentiation, increased
mitochondrial oxidative
stress.
[67,70,71]
drial IM. Hereditary X-linked
sideroblastic anemia
and cerebellar ataxia
Mouse conditional KO has
defective hematopoiesis,
sideroblastic-like anemia,
ataxia and hepatocellular
iron deposits.
[75–77,79]
e.
?
Hereditary familial
folate malabsorption,
folate-responsive
anemia in newborns
Mouse KO has increased
Nhomocysteine protein
levels.
[139,241,249]
/
.
Transient knockdown of
zebraﬁsh ortholog results in
hydrocephalus, yolktube
malformations and a
profound defect in
erythropoiesis.
[150,248]
e.
[150,248]
Fig. 1. The heme biosynthesis pathway and putative mitochondrial transporters. The ﬁrst step of heme synthesis occurs in the mitochondrial matrix with the condensation of
succinyl-CoA and glycine by ALAS to generate ALA. ALAmay be exported in exchange for glycine by an IM transporter SLC25A38. Themechanism of ALA export across the OM into the
cytoplasm is unknown. ALA is converted to CPgenIII by four enzymatic reactions. CPgenIII is then transported back into the mitochondrial intermembrane space (IMS), possibly via
ABCB6, where it is converted to PPgenIX by CPO. The conversion of PPgenIX to PPIX by PPO, its transport into thematrix and the addition of Fe+2 by ferrochelatase (FECH) to generate
heme are coupled processes, with transport of PPIX likely occurring via a proposed direct channeling through a complex of PPO–FECH (likely part of a larger complex with the
mitochondrial iron importer, Mitoferrin, ABCB7 and ABCB10). The transfer of heme from the matrix to the IMS, for respiratory chain cytochrome assembly, may be mediated by
ABCB10; the transporter responsible for its transfer across the outer mitochondrial membrane remains unidentiﬁed. See text for details.
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cytosolic enzyme to the next in the pathway is at present unknown,
but a macrocomplex comprising all four cytosolic enzymes, as has
been proposed for the terminal pathway enzymes (see below), may
occur. CPgenIII is then transported back across the OM into the
mitochondrial intermembrane space (IMS). Krishnamurthy et al.
suggest that an ATP-binding cassette transporter ABCB6 is involved in
porphyrin transport across the OM [47] (reviewed in [48]).
Cell surface ABC transporters serve to efﬂux a variety of compounds,
including xenobiotics in eukaryotic cells [49,50]. In addition, family
members are involved in mitochondrial transport [51]. These transpor-
ters have a characteristic structure consisting of two transmembrane
domains (TMD) and two intracellular nucleotide-binding domains
(NBD). Energy derived from hydrolysis of ATP by the NBD provides
energy for the uphill movement of substrates across membranes.
Approximately 50 ABC transporters have been identiﬁed in the human
genome and classiﬁed into seven subfamilies (A–G) based on the
structure of their ATP-binding domains.
ABCB6 was initially identiﬁed as a mitochondrial protein that
functionally complements the Saccharomyces cerevisiae atm1-1
mutant [52] that encodes Atm1p, a yeast mitochondrial IM protein
believed to be involved in the biogenesis of cytosolic Fe–S clusters
[53]. Fe–S clusters aremodular protein cofactors consisting of iron and
sulfur, which are usually linked by bonds joining the cysteine sulfur
atoms of a polypeptide protein to iron atoms of the cluster. Fe–Sclusters function as part of enzyme catalytic centers (e.g., aconitase,
succinate dehydrogenase), in chemical sensing, electron transfer and
generation of radicals [54–56]. Similar to mutations of other genes
involved in eukaryotic Fe–S cluster biosynthesis (e.g., human fxn and
glrx5; see [56] for review) Atm1 mutants accumulate free iron in the
mitochondria and have depressedmitochondrial respiratory function,
which is almost completely reversed by expression of human ABCB6
[52,57]. However, unlike its mitochondrial IM paralog ABCB7, ABCB6
is localized to the OM in the human erythroid cell line K562 [47,58]
(although exclusive mitochondrial localization of ABCB6 in other cell
types has been disputed; see [59–61]), and studies demonstrate
conclusively that ABCB7 is the true Atm1 ortholog [62]. Nonetheless,
ABCB6 is upregulated by hemin or DMSO-induced differentiation of
the murine erythroid cell line MEL cells [47] and a recent large-scale
expression analysis of genes associated with heme biosynthesis also
identiﬁed ABCB6 [63]. ATP- and temperature-dependent inward
transport of 55Fe-hemin into mitochondria isolated from K562 cells
overexpressing ABCB6 has been demonstrated [47]; inward transport
(although non-physiological) is consistent with the presence of the
nucleotide-binding domain in the cytosol. The oxidized form of the
physiological heme synthesis intermediate CPgenIII, coproporphyrin
III (CPIII) competes with mitochondrial 55Fe-hemin uptake and
dissociates ABCB6 from hemin-agarose [47]. However CPIII is not a
heme synthesis pathway intermediate and it remains to be estab-
lished whether ABCB6 functions in CPgenIII uptake.
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the mitochondrial IMS enzyme, coproporphyrinogen oxidase (CPO)
and protoporphyrinogen oxidase (PPO), are required to convert
CPgenIII into protoporphyrin IX (PPIX); the latter was proposed to be
transported across the IM into the matrix by adenine nucleotide
translocator (ANT), without requiring ATP energy [64]. However,
because the enzymes PPO and ferrochelatase (Fech), catalyzing
respectively the penultimate and ﬁnal steps of heme synthesis, are
both localized at the mitochondrial IM–PPO is an IMS-facing protein
while Fech is exposed to the matrix—a channeling of PPgenIX and
PPIX through a complex formed by PPO and Fech within the IM is
more likely, based on biochemical studies [65] and the crystal
structure of the two enzymes [66]. The ﬁnal step, the addition of
one atom of Fe2+ to PPIX by Fech that results in the formation of
protoheme or heme b occurs on the matrix side of the IM,
necessitating its transfer, by as yet unidentiﬁed transporters, across
both the IM and OM again in order to reach the cytosol.
Recent studies indicate that Fech interacts with mitoferrin-1
(Mfrn1)—a mitochondrial IM protein involved in mitochondrial iron
uptake that is upregulated during erythroid differentiation [67]. Like
ALAS, there are two forms of Mfrn in zebraﬁsh and mammals, Mfrn1
and Mfrn2, respectively, with Mfrn1 uniquely important for iron
import in developing erythroid cells [68]. Elegant studies subse-
quently showed that Mfrn1 but not Mfrn2 was stabilized in a post-
translational manner during erythroid differentiation [69]. Chen et al.
then isolated an IM ABC transporter, ABCB10 (formerly ABC-me;
[70]), among a number of proteins that were precipitated with Mfrn1
isolated from mitochondria derived from MEL cells undergoing
erythroid differentiation. Their studies demonstrate that ABCB10
stabilizes Mfrn1 during erythroid differentiation, to allow for high
efﬁciency iron uptake into mitochondria for optimal heme synthesis
[71]. Notably, in undifferentiated MEL cells, forced expression of
Abcb10 and Mfrn1 enhances Mfrn1-mediated 59Fe uptake by mito-
chondria approximately 2-fold, but has no effect on mitochondrial
59Fe-heme levels. It was proposed that this lack of heme synthesis was
due to an inadequate supply of protoporphyrin precursors [71];
however an accompanying commentary speculated that Fech levels
may be limiting and that the enzyme formed part of a macromolecular
complex with Mfrn1 and ABCB10 [72]. In fact, further studies have
shown that the expression of all three proteins is co-induced during
MEL cell erythroid differentiation, whereas analysis of the higher
order protein complexes of Mfrn1 during differentiation indicates that
Mfrn1 and ABCB10 transiently interact with Fech [73]. Previous
studies had shown that MEL cells transfected with Abcb10 undergoing
erythroid differentiation had enhanced hemoglobin synthesis (2–4-
fold; [70,74]). Yet overexpression of ABCB10 alone does not initiate
erythroid differentiation or alter the timing of hemoglobin synthesis
upon differentiation. It would be interesting to discern whether the
structural role of ABCB10 in stabilizing Mfrn1 is sufﬁcient to produce
enhanced Hb levels or whether ABCB10 transport function is required.
The potential substrate of ABCB10 has not been identiﬁed, but
heme is a possible candidate. Mfrn1 is found in higher-order protein
complexes than those predicted from a macromolecular complex of
Mfrn1–ABCB10–Fech suggesting that yet unidentiﬁed proteins are
also part of a multi-protein complex at the IM. Chen et al. speculate
that PPO and perhaps CPO are also present in this complex to allow
coordinated supply of PPIX and Fe2+ to Fech for heme synthesis [73]
(and perhaps coordinated heme transport by ABCB10).
In addition to its use for heme synthesis, mitochondrial iron is also
utilized for mitochondrial Fe–S cluster biogenesis. Fech possesses a
[2Fe–2 S] cluster that is not required for catalytic function, but the
enzyme is sensitive to the availability of Fe–S clusters. Rouault's group
has recently shown that when Fe–S cluster synthesis is impaired, due
to deﬁciency of proteins required for Fe–S cluster biosynthesis or iron
deﬁciency, apo-Fech is rapidly degraded in the mitochondria,
potentially providing a direct link between Fe–S cluster and hemesynthesis [75]. Asmentioned, themammalian IM transporter ABCB7 is
the yeast Atm1 ortholog and appears to be important for cytosolic but
not mitochondrial Fe–S cluster biogenesis [76]. Mutations in the
human Abcb7 gene result in defective cytosolic Fe–S-containing
protein maturation and mitochondrial iron overload, leading to an
X-linked congenital sideroblastic anemia with ataxia [77,78]. Prior to
the identiﬁcation of cytosolic Fe–S cluster biogenesis (review; [79]) it
was believed that ABCB7 was involved in mitochondrial Fe–S cluster
export. More recent studies suggest that it exports a substrate
important for cytosolic iron homeostasis or a signal of mitochondrial
iron status, with deﬁciency of this signal indicating depletion of
mitochondrial iron and resulting in diversion of cytosolic iron to the
mitochondria [76]. The speciﬁc reason for the impaired heme synthesis
observed in Abcb7 knockout mice remains unclear. The physical
interaction of ABCB7 with the C-terminal region (Fe–S ligation site) of
Fech has been proposed to function in mitochondrial iron homeostasis
[80]. The knockout mouse model shows elevated mitochondrial iron
levels without an increase in PPIX levels, yet zinc PPIX levels are
increased (which requires functional Fech) suggesting that ABCB7 plays
a role in the availability of iron destined for incorporation into PPIX by
Fech [78].
Nilsson and colleagues recently performed a large-scale gene ex-
pression analysis to identify potential mitochondrial transporters of
heme and heme synthesis intermediates, seeking genes co-expressed
consistently and speciﬁcally with genes encoding enzymes of the heme
synthesis pathway [63]. Reassuringly, ABCB6, ABCB10 andMfrn-1 were
identiﬁed, as expected. The transporters SLC25A39, TMEM14C, and
SLC22A4 and the Fe–S cluster biogenesis proteins ISCA1 and C1orf69
were identiﬁed as potential candidates involved in mitochondrial
heme/iron metabolism. Silencing of each candidate gene in zebraﬁsh
results in an anemic phenotype. SLC25A39 was the only gene
characterized in detail. Silencing of this gene in differentiating MEL cells
results in a 4-fold decrease in the 59Fe-heme content of mitochondria,
without the accumulation of 59Fe. The authors predict a role for SLC25A39
in Fe–S assembly that affects heme synthesis.
3. Heme catabolism and the need for heme transport
Although chemical degradation of heme occurs in mammals
through the action of H2O2 or ascorbic acid [81,82], the HO system
is the major physiologically relevant mechanism of heme catabolism
(for review see [83]). In humans, HO is present in two functionally
active isoforms, HO-1 and HO-2, encoded by different genes and, apart
from their heme degradative function, dissimilar in molecular and
biochemical properties. A pseudogene variant of HO-2, HO-3 has also
been described in the rat brain [84–86].
HO is a mixed function oxidase, i.e., it utilizes molecular oxygen,
generating oxidized products and H2O. The oxidase catalyzes the
regio-speciﬁc cleavage of the α-methine bridge of heme-producing
iron, CO, and biliverdin IXα (BV)—and is the rate-limiting step in the
degradation sequence. The concerted activity of NADPH-cytochrome
P450 reductase is also necessary, both to supply electrons and to
activate oxygen. BV, a physiological inhibitor of HO function, is rapidly
converted to bilirubin IXα (BR) by BVR. HO and NADPH-cytochrome
P450 reductase are located in the endoplasmic reticulum (ER),
forming a complex with each other and, at least in vitro, with cytosolic
BVR [87]. Incidentally, HO-1 has also been localized to plasma
membrane caveolae (with NOS and BVR [88]), mitochondria, and
the nucleus [89,90]. BR is, in turn, conjugated in the liver by UDP-
glucuronyl transferase and eventually excreted into the bile. The daily
production of BR in man is ~400 mg, of which ~300 mg is derived
from Hb breakdown [91].
In bacteria, breakdown of imported heme serves primarily as a
source of iron, and early studies in mammals likewise focused for the
most part on the importance of HO for heme catabolism during Hb
breakdown. However, it is now well recognized that HO-mediated
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oxidative and iron reutilization functions.
3.1. Antioxidative function of HO-1 and HO-2
HO-1 is activated by a greater number of stimuli than that of any
other gene [83]. It is inducible by increased heme levels; various
metals (including sodium arsenite, cobalt and selenium); hypoxia in
certain cell types; hyperoxia; environmental chemicals; H2O2; NO;
depletion of intracellular glutathione; UV light; and heat shock (and
thus known as HSP32). Notably, basic leucine zipper (bzip) “stress-
responsive” transcription factors, including members of the ATF
family, c-Fos, c-Jun and Nrf2, maf family members and Bach-1, all
regulate HO-1 expression. These transcription factors function as
homo-dimeric transcriptional complexes or, with other bzip mem-
bers, as hetero-dimeric transcriptional complexes, vastly expanding
the scope of HO-1 regulation [92,93]. More recently, BVR has been
identiﬁed as a key regulator of HO-1 expression. The enzyme has
kinase, transcription factor and intracellular heme transport activities.
Thus BVR can serve as a dimeric bzip transcription factor; or through
its kinase function, directly phosphorylate and regulate other bzip
members; or via transport of heme into the nucleus enable
derepression of Bach-1-mediated repression of HO-1 [92–94]. An
overriding principle of HO-1 expression appears to be its rapid
induction in response to an increase in cellular oxidative stress and
then subsequent repression to low levels.
In contrast, HO-2, the predominant form of HO protein in the brain
and testis, is constitutively expressed in all cells, with the promoter
responding solely to glucocorticoids (for review see [83]). The N-
terminus of HO-2 protein contains heme-binding Heme Regulatory
Motifs (HRMs) consisting of CP-based short amino acid sequences
[95], an ancientmotif found in proteins that function as heme–oxygen
sensors in bacteria [27], yeast (HAP-1 [41]) and mammals (ALAS2,
Bach-1 and HRI [8,9,11]). The presence of HRMs thus suggested a
further function for this enzyme—that of an intracellular sink, binding
and regulating (or “sensing”) the heme gaseous ligands NO, CO and
O2. Subsequently, HO-2 has been shown to co-localize with NOS,
binding the vasodilator NO with high afﬁnity [96] and, with less
afﬁnity, the potential vasodilator CO, or O2. Furthermore, HO-2
interacts with and, through proximal production of CO, stimulates
the calcium-sensitive potassium (BK) channels that mediate the
excitatory responses of the carotid body to hypoxia [97]. HO-2−/−
mice have mild hypoxemia and their carotid bodies are enlarged (as
also seen in patients with chronic hypoxemia [98]); however, their
carotid bodies respond normally to acute hypoxia [99], and the mice
have only partially impaired acute ventilatory responses and
(proposed) chronic pulmonary ventilation/perfusion mismatches,
perhaps related to changes in CO signaling [100]. Thus it is postulated
that redundant mechanisms, including CO, NADPH-oxidase and AMP:
ATP ratios, regulate the acute response of both central and peripheral
chemoreceptors to hypoxia through inhibition of ion channels [101].
In addition, HO-1 appears to be upregulated in the lungs of HO-2−/−
mice, perhaps functioning as an alternate source of CO production.
Recent studies indicate an additional role for the HRMs of HRM-
containing proteins like HO-2; that of a thiol/disulﬁde redox switch
that responds to the cellular redox state. Thus, during oxidative stress,
heme binds with a much higher afﬁnity to the disulﬁde cysteine
residues, increasing its function as a sink for NO and derivatives, CO
and O2, while, under reducing conditions, the cysteines would become
thiols and thus have a lower afﬁnity for heme [102].
The reason for the reduction of the heme catabolite BV to BR has
been questioned, as BV is water soluble and thus easily excreted,
whereas BR is lipid soluble and believed to be toxic. However, studies
by Stocker et al. [103], extended by Snyder's laboratory [104–106] and
others, have clearly shown that BR at intracellular nanomolar (i.e.,
physiological) concentrations is a potent antioxidant that protectscells from up to a 10,000-fold excess of H2O2; in so doing, it is itself
oxidized to BV, which is then recycled back to the reducing agent BR
through the action of PKC-dependent signaling that activates BVR
[105]. In neurons this reaction depends on the substrate BV being
supplied by HO-2, rather than by HO-1 [106]. Recent studies indicate
that BR serves mostly to defend lipid membranes from ROS, whereas
the other major intracellular antioxidant, the water-soluble glutathi-
one system (GSH/GSSG), protects water-soluble proteins [104].
In closing this section on the antioxidant function of HO, we should
note that there have been reports suggesting that HO-1 induction
could be harmful to the cell under certain circumstances (see [92]). In
particular, the release of heme–chelated ferrous iron that could
potentially interact with H2O2, producing the highly toxic hydroxide
radical (the Fenton reaction), is seen as problematic. Yet, provided the
iron released is either sequestered by storage within ferritin or
exported out of the cell by the cell membrane iron exporter
ferroportin (FPN1) [107,108], then an increase in HO-1 activity
should be beneﬁcial to the cell. One group found that transfection of
human cells with catalytically inactive rat HO-1 (mHO-1) provided
greater protection from (very high levels of) H2O2 than transfection
with wild-type HO-1, an effect reversed by treatment of the cells with
a HO inhibitor (zinc protoporphyrin) or iron chelators. They also
noted an inverse correlation between the levels of glutathione and
catalase and HO-1 activity [109]. One could argue that these are not
physiologic studies; HO-1 is never induced in cells for long periods of
time, as heme levels may fall precipitously, perhaps leading to
decreases in catalase and other heme-containing antioxidant proteins
(see [58]). Ferris et al. noted equivalent levels of ferritin in HO-1−/−
cells and cells overexpressing HO-1 [110]. Similarly, a study published
recently demonstrates a lack of ferritin synthesis, despite HO-1
induction, in a cell-line in response to oxidizing reagents (as opposed
to an appropriate response to extracellular heme) [111]. As the known
intracellular level of free heme is very low, it was suggested that there
is insufﬁcient substrate for HO-1, or that it perhaps acts through other,
non-enzymatic mechanisms [111]. However, one could also speculate
that under oxidative stress all available iron is shunted directly to the
mitochondria for heme synthesis for heme-containing antioxidant
proteins, without a concomitant increase in ferritin synthesis.
Moreover, as these investigators acknowledge, they may be unable
to measure the small quantity of heme degradation that occurs during
exposure to oxidative stress. In sum, there is a large body of literature
that supports a seminal role for the HO system, in particular the
inducible HO-1 enzyme, in protecting cells from oxidative stress,
provided the result is limited heme degradation, which might
otherwise limit the function of other critical cell hemoproteins.3.2. Iron reutilization function of HO-1 and HO-2
Under normal physiological conditions, ~25 mg of iron is con-
sumed daily by immature erythrocytes in the bone marrow (BM) for
heme biosynthesis. As the daily dietary iron intake is 1–2 mg,
recycling of heme–iron from senescent erythrocytes constitutes the
main source of iron for erythropoiesis. Erythrophagocytic macro-
phages in the liver, spleen and BM are responsible for this recycling.
Hb-derived heme is catabolized by HO-1 to release iron, which is
subsequently exported into circulation by the sole cell iron exporter
FPN1 (reviews [112,113]). Hemoglobin also appears in the plasma
under physiological conditions due to intra-vascular hemolysis of
senescent erythrocytes (~10% [114]) and during enucleation of
erythroblasts in the BM. Hemoglobin is bound by haptoglobin for
delivery to CD163-receptor-bearing macrophages, whereas any free
heme is rapidly bound to albumin and lipoproteins before being
passed on to the high-afﬁnity heme binding plasma protein Hpx
(review [115]). Hpx–heme complexes undergo (LRP1/CD91) recep-
tor-mediated endocytosis by hepatic parenchymal cells; however,
673A.A. Khan, J.G. Quigley / Biochimica et Biophysica Acta 1813 (2011) 668–682they can also be taken up by macrophages, neurons and syncytio-
trophoblasts [116].
In approaches to determining the relative contributions of HO-1
and HO-2 to erythrocyte heme–iron recycling, both HO-1−/− and HO-
2−/− mice were generated [117,118]. In contrast to HO-1−/− mice,
HO-2−/− mice have no evidence of disturbed iron homeostasis, apart
from increased pulmonary iron in the setting of hyperoxia [119]. As
mentioned, it is likely that the inducible enzyme HO-1 is upregulated
in HO-2−/− mice. A patient with homozygous HO-1 deﬁciency has
been described [120]; the child, who died at age 6 years, had evidence
of severe hemolytic anemia with high serum heme levels, low serum
bilirubin, absent Hpx, increased haptoglobin, and hypoferremia. Very
high von Willebrand Factor and thrombo-modulin levels and
disseminated intravascular coagulation were observed, indicating
endothelial injury. The child also had hyperlipidemia, and, at autopsy,
aortic atheromas were noted. There was iron overload of the liver
(involving both the hepatic reticulo-endothelial system [RES] Kuppfer
cells and parenchymal cells) and kidney (proximal tubule epitheli-
um). The ﬁndings are consistent with an important role for heme
catabolism both in protection of the vascular endothelium from
potentially high levels of exposure to heme and for heme–iron
reutilization. HO-1−/− mice develop a similar iron overload pheno-
type [110,117] that becomes evident between 20 and 40 weeks, with
twice the amount of iron in the liver at 10 weeks, when compared
with controls. The erythrocytophagocytes of the liver (Kuppfer cells)
showed evidence of iron overload, but no excess iron deposition was
observed within splenic erythrocytophagic macrophages; the spleen
however, was enlarged due to increased hematopoiesis (the child had
asplenia). More recently, the murine model of HO-1 deﬁciency has
been re-examined at various ages between 1.5 and 22 months [121].
The animals develop asplenia over time, due to ﬁbrosis and loss of the
red pulp. Notably, there is a marked loss of erythrocytophagocytes in
the liver spleen and BM, which is shown to be due to the toxicity of
heme released within macrophages during ingestion of senescent
erythrocytes. The authors suggest that the high levels of haptoglobin
observed in the human subject with HO-1 deﬁciency are explained by
the speciﬁc loss of erythrophagocytic macrophages (which also bear
the haptoglobin receptor CD163). Iron loading of the proximal tubules
of the mouse kidney was seen as previously, and splenic tissue iron
levels were low (due to a lack of macrophages). Notably, liver tissue
non-heme iron levels were similar to controls, however the
distribution was altered, with iron found in hepatocytes, perhaps
from Hpx–heme delivery, rather than in (the reduced numbers of)
Kuppfer cells. Although HO-2 knockdown in mice is not associated
with disordered systemic iron homeostasis, it has been postulated
to contribute to iron homeostasis in liver parenchymal cells
[122]. Finally, when HO-1−/− BM cells are transplanted into irradiated
HO-1+/+ mice, the animals show no evidence of hepatic or renal iron
overload at 20 weeks, suggesting a role for endothelial, hepatic and
renal parenchymal HO-1 in heme–iron recycling [117]. In sum, the
analysis by Kovtunovych et al. indicates that the loss of erythropha-
gocytic macrophages from heme toxicity, resulting in a large increase
in circulatory heme and Hb is the key to the pathogenesis of HO-1
deﬁciency [121].
Hepcidin is the hormone that regulates systemic iron homeostasis
through binding to and thus decreasing the cell-surface expression of
FPN1 [123]. Hence, it regulates both enterocyte iron absorption and
the release of iron from erythrocytophagic macrophages. Hepcidin is
itself regulated by iron, erythropoiesis, tissue hypoxia and inﬂamma-
tion (review [124]). Of interest, FPN1 and HO-1 are co-induced in
macrophages upon ingesting erythrocytes, whereas macrophages
from HO-1−/− mice have chronically high levels of FPN1 expres-
sion [121], likely related to the presence of a heme-inducible MARE/
ARE element in the enhancer region of the gene [125]. Recent studies
have shown decreased hepcidin levels in a HO-1-deﬁcient patient
[126], despite evidence of chronic inﬂammation, which normallyincreases hepcidin levels, whereas studies of the murine HO-1−/−
animal demonstrate normal hepcidin levels [121]. These ﬁndings
reiterate the predominance of the proposed erythroid iron regulator
[127] and serum hypoferremia in suppressing hepcidin to allow for
the ﬂow of iron from the RES to the BM for erythropoiesis.
As expected, human and murine HO-1−/− cells rapidly undergo
apoptosis upon exposure to heme [120], and HO-1−/−mice also have
evidence of increased oxidative stress, with increased free radical
expression in response to heme, H2O2, paraquat or CdCl2 [128]. The
mice are extremely sensitive to endotoxemia, dying upon exposure to
low doses of lipopolysaccharide. Notably, these deaths are due to
massive parenchymal hepatocyte iron loading, resulting in liver
necrosis. A similar hepatocyte injury pattern is seen when Hpx-null
mice are given moderate intravenous doses of hemin; that is, the
majority of intravascular heme ends up in the liver parenchyma
(presumably bound to albumin and LDL [115]), resulting in hepatic
inﬂammation and congestion, likely secondary to sinusoidal injury
and thrombosis. This inﬂammation is prevented by prior induction of
HO [129]. Hershko et al. reported hepatic and RES iron loading in a rat
model of inﬂammation more than three decades ago [130]. After
injection of heme in the form of damaged erythrocytes or Hb, there
was increased catabolism of heme to ferritin, as well as a decrease in
ferritin secretion. It is now acknowledged that the iron loading of RES
and hepatic parenchymal cells in response to inﬂammation is, for the
most part, secondary to a lack of release of iron from these cells due to
cytokine-mediated upregulation of hepcidin, decreasing FPN1-medi-
ated iron export [131]. Presumably HO-1 is upregulated to cope with
the heme load. It is unknown why or how mobilization of iron and
heme to the liver occurs with inﬂammation/infection. It may be a
protective mechanism to decrease the levels of both iron and heme–
iron in the systemic circulation, thus preventing bacterial access to
iron (iron in ferritin is likely inaccessible to bacteria) or, perhaps, as
Poss and Tonegawa propose, to reduce oxidative stress in the tissues
[128].
In summary, both HO-1 and, to a lesser extent, HO-2 are important
for heme–iron re-utilization. What is striking, however, is the
longevity of the HO-1 knockout animals, given the low-level
expression of HO-2 (e.g., there appears to be no upregulation of HO-
2 in PBMCs isolated from the patient with HO-1 deﬁciency [120]), and
the enormous iron requirement for continued high level erythrocyte
production in the face of severe hemolysis. This observation would
suggest that there are othermethods of recycling heme–iron. Poss and
Tonegawa suggest contributions from amicrosomal cytochrome P450
reductase and a cytosolic xanthine oxidase [117]. In the following
sections we will discuss the potential importance of FLVCR-mediated
heme export.
4. Heme absorption
Ingested heme serves as the most important source of dietary iron
in meat-eating animals [3,132], comprising one-third of ingested
iron in Western diets but up to two-thirds of absorbed body iron. This
is likely related to the increased bioavailability of heme relative to
iron, especially when bound to proteins [133–135]. Unlike expression
of the duodenal iron importer (DMT1, [136]), which increases
approximately 10-fold during iron deﬁciency, intestinal heme uptake
increases 3-fold, suggesting a separate, carrier-mediated process
[137]. Although the molecule(s) mediating duodenal brush-border
enterocyte heme uptake has not been identiﬁed, considerable
evidence suggests uptake occurs via a receptor-mediated endocytotic
pathway (see [138] and [134] and references therein) or by heme
importer(s) (possibly HCP1 [139]; see below). Early studies demon-
strated the presence of a mammalian enterocyte heme-binding protein
that binds heme with high afﬁnity (Kdiss up to 10−9 M [140]), with
binding subsequently lost upon treatment of the cellswith trypsin.More
recent studies indicate heme uptake is temperature dependent and
674 A.A. Khan, J.G. Quigley / Biochimica et Biophysica Acta 1813 (2011) 668–682saturable, decreased by inhibition of oxidative phosphorylation, but
unaffected by ATP depletion [141–143]. Similar ﬁndings in mammalian
erythroid and hepatic tissue cell lines suggest heme import is a
generalized cell process [141,144]. Two separate electron microscopy
studies of closed mammalian duodenal loop tissues indicate that heme
is taken up intact by enterocytes—subsequently appearing ﬁrst in apical
tubulo-vesicular structures within the cytosol and then in secondary
lysosomes [145,146]. Notably, heme disappeared from these vesicles
within 3 h and was not present in the basolateral regions of the cells,
the extracellular space or the portal vein, indicating intracellular
catabolism, consistent with ﬁndings in mammals, including humans,
where the majority of ingested radioactive Hb iron is detected in the
portal vein as non-heme iron within 2–3 h [133,147,148]. In this
scenario, either the endosome/lysosome possesses HO activity and an
iron transporter for ferrous iron, such as DMT1 [136] or TRPML1 (see
review; [149]), or perhaps the lysosomal heme transporter HRG-1
delivers heme to the cytosol ([150]; discussed below). HO is
upregulated 2.5-fold in rat enterocytes in response to iron deﬁciency,
and enzyme activity is highest in the proximal small intestine, the site of
maximal heme absorption [151–153]. Studies in dogs conﬁrm that HO
activity is limiting for heme absorption [154], while HO inhibitors – e.g.,
Sn mesoporphyrin (po or iv) – inhibit intestinal heme absorption and
result in increased biliary excretion of heme [155]. Surprisingly, recent
confocal microscopy studies of rat enterocytes after heme dosing show
that, while HO-1 is distributed throughout the cell, HO-2 is the enzyme
found exclusively in the subapical region, where it co-localizes ex-
tensively with endosomes [156].
In contrast to these studies on the importance of HO-mediated
heme catabolism for heme–iron absorption, an older study of Hb
absorption in guinea pigs suggested the absorption of intact heme
[157]. In addition, in the human enterocyte—like cell line, Caco2,
which has very high expression of the heme exporter FLVCR, heme
appears to be exported across both the basolateral and apical surfaces
[158]. In addition, haptoglobin gene knockout in mice causes fpn1
upregulation in intestinal cells, which may also suggest the uptake of
heme from the circulation into intestinal cells [159].
In summary, in most mammals, dietary heme is transported intact
into intestinal mucosal cells, where it is mostly catabolized, with the
subsequent appearance of inorganic iron in the portal vein. Systemic
hememay also be taken up by hepatic (or perhaps intestinal) cells and
transferred, if necessary, into the gastrointestinal lumen [160].
5. Heme trafﬁcking and transporters
Both cell surface and organelle-associated heme transporters are
likely involved in the sequestering and trafﬁcking of intracellular
heme (Fig. 2; see also reviews [39,48,138,161–164]). Because the last
step of endogenous heme synthesis occurs in the mitochondrial
matrix, heme must traverse both mitochondrial membranes to enter
the cytoplasm (Fig. 1). Although the identity of the mitochondrial
heme exporter is unknown, ABC transporter family members may
channel heme synthesis intermediates across both mitochondrial and
plasma membranes (see Sections 2 and 5.1.2) [47,165]. Heme is also
known to function as a transcriptional regulator; therefore, it must
enter the nucleus, probably through binding to a carrier protein such
as BVR [32]. Approximately 85% of synthesized heme is utilized for Hb
production in the BM. The other 15% is produced in the liver, primarily
for cytochrome (especially P450) synthesis in the ER and for catalase
synthesis in peroxisomes, suggesting the presence of heme transpor-
ters in these organelle membranes [39,166]. Thus, heme needs to be
transferred to various compartments within the cell, presumably
chaperoned by cytosolic heme-binding proteins (reviewed in [39])
However, the identity of the intracellular heme-binding proteins and
many of the heme transporters has not yet been identiﬁed. In the next
section, the current understanding of various established and
potential heme transporters is discussed.5.1. Heme exporters
5.1.1. FLVCR, a cell surface heme exporter
Infection of cats with Feline Leukemia Virus subgroup C (FeLV-C)
invariably causes a severe non-regenerative anemia (hematocrit 4%–
15%), with an absence of reticulocytes in the circulation and
hemoglobinized cells in the BM, despite high erythropoietin levels.
Studies have subsequently shown evidence of an arrest in erythro-
poiesis at the colony-forming unit-erythroid progenitor (CFU-E)/pro-
erythroblast stage [167,168], where heme synthesis begins [169,170].
The disease bears a resemblance to human pure red cell aplasia
because, despite viral infection of all BM cells, there is normal devel-
opment of the myeloid and megakaryocytic lineages [171]. FeLV
subgroups (A, B and C) were deﬁned by host cell range, neutralization
and interference assays that indicate their viral envelopes exploit
different cell receptors [172,173]. The nonpathogenic FeLV-A has a
narrow host range, while both FeLV-B and FeLV-C have broad host
ranges. The genomes of FeLV A, B and C are most divergent in the
segment that encodes for variable region 1 (VR1) of their envelope
proteins. In studies using chimeric envelope genes of FeLV-A and FeLV-
C, an 11-aa sequence of VR1 of FeLV-C envelope protein was sufﬁcient
to transform FeLV-A into a pathogenic feline virus causing anemia
[174]. This suggests that the anemia is caused by a dominant negative
effect of the FeLV-C envelope protein interferingwith the display and/
or function of its receptor on CFU-E/pro-erythroblasts. As the function
of the receptor appeared to be critical for the development of erythroid
progenitors we and others functionally cloned the gene, termed Flvcr,
Feline Leukemia Virus subgroup C Receptor [175,176].
5.1.1.1. Gene, protein structure and expression. FLVCR is highly
conserved throughout evolution with orthologs present in animals,
plants and bacteria, suggesting an important role in cell biology [177].
The human gene (also known as Mfsd7b) is located at chromosome
1q32, contains 10 exons and spans approximately 40 Kb. The promoter
region contains consensus GATA-1, GATA-2 and STAT5a binding sites,
providing potential mechanisms for upregulation of the gene during
early erythroid development [36]. Of interest, both FLVCR and one of its
3 paralogs (on chromosome 3q, GI:74732717) have an adjacent gene
upstream that shares the same promoter; LQK-1, 177 bps upstream of
FLVCR, is of unknown function, whereas the 3q gene product HSPBAP1,
binds HSP27, an antioxidant protein [178]. In addition, there is a
marked homology between a group of genes that includes FLVCR on
chromosome 1q and a paralogous cluster that includes FLVCR2 on
chromosome 14q, a duplication that occurred over 500 Ma ago [177].
Such clustering of genes has been previously associated with functional
linkage—e.g., the murine surfeit locus [179].
Themajormature FLVCR transcript encodes aproteinof 555 aawith a
predicted molecular weight of 60 kDa and a pI of 5.72 (Fig. 3). The
protein belongs to themajor facilitator superfamily (MFS) of secondary
permeases,which transport small solutes suchas glucose (e.g., GLUT-1),
amino acids, and ions across cell membranes in response to chemico-
osmotic gradients. Topology predictions indicate that FLVCR is a 12-
transmembrane domain protein with both N- and C-termini inside the
cell. Both the N- and C-termini of MFS transporters generally contain
domains important for transporter trafﬁcking and proper localization—
e.g., in the polarized epithelial cells of the intestine and kidney [180].
FLVCR has both a proximal tyrosine-basedmotif YXXØand amore distal
di-leucinemotif in the N-terminal intracytosolic region. These signals in
mammalian proteins mediate rapid internalization and targeting to
endosomal–lysosomal compartments, suggesting that FLVCR may be
targeted to these locales. Sequences conforming to this motif have
also been implicated in baso-lateral targeting in polarized epithelial
cells [181,182]. In addition, the C-terminus contains a PDZ domain-
binding motif that likely promotes protein–protein interactions (see
below and reviews [183,184]). Both the putative human heme importer
PCFT/HCP1 and the C. elegans lysosomal heme transporter HRG-1 (see
Fig. 2. A generalized depiction of known and putative cell-surface and organelle-associated heme transporters. FLVCR is a cell-surface heme exporter. ABCG2 is a potential cell-
surface heme exporter; HCP1 is a putative heme importer. CD163 receptor-mediated endocytosis of the Hp:Hb complex suggests the existence of an endosomal/lysosomal heme
exporter; HCP1 or HRG1 may fulﬁll these role(s). The transporters that mediate import of heme into peroxisomes and lysosomes for assembly of catalases and peroxidases are
unknown (it is also unclear at present where ﬁnal assembly of hemoproteins occurs). Heme is transferred into the nucleus in association with BVR, while cytoplasmic heme appears
to be chaperoned by proteins such as glutathione S-transferase B and HBP23. See text for further details. Putative transporters of mitochondrial heme and heme biosynthesis
intermediates are shown in detail in Fig. 1.
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domain-binding motif.
Human FLVCR mRNA is expressed ubiquitously with the highest
expression observed in the liver, duodenum, kidney, lung, spleen, brain,
placenta and BM (including CD34+ stem/progenitor cells) [36,37].Fig. 3. FLVCR membrane topology. FLVCR is predicted to contain 12-transmembrane
domains, with both N- and C-termini within the cell. It has di-leucine (LL) and YXXØ
and motifs (where Ø denotes a hydrophobic amino acid) in the N-terminal region that
may allow proper membrane domain targeting and recycling. His and Tyr residues in
the extracellular loops are predicted to be important for heme binding/transfer,
whereas Tyr residues in the large intracellular loop may serve as targets of kinases and
phosphatases. The 4-aa PDZ domain-binding motif at the C-terminal region is
important for its interaction with the PDZ domain of the nonreceptor tyrosine
phosphatase PTPN3.Notably, in studies of human erythropoiesis, speciﬁc upregulation of
FLVCR protein expression is observed at the CFU-E stage; FLVCR is
subsequently downregulated with further differentiation [36]. There are
wide disparities between mRNA levels and cell surface protein
expression (see [36,37]) suggesting that posttranslational control
mechanisms, such as protein trafﬁcking, regulate FLVCR expression.
This is not unexpected as regulation of transporter cycling is a control
mechanism important in the cell surface expression of other MFS
members, such as glucose and iron transporters (e.g., GLUT-4 [185];
Arn1p [186]).More recently, alternative splicingof FLCVRmRNAhasbeen
described, with enhanced alternative splicing resulting in reduced levels
of the normal protein observed in erythroid cells from patients with a
congenital form of red cell aplasia, Diamond-Blackfan anemia (DBA)
[187]. In earlier studies we found no evidence of FLVCR gene mutations
in a subset of DBA patients with linkage to the FLVCR locus [188].
Of interest, a recent study describes homozygous missense
mutations in FLVCR in affected individuals from three families with
a syndrome of posterior column ataxia and retinitis pigmentosa [189].
Analysis of murine posterior column neurons and retinal tissues
shows high expression of FLVCR. The authors hypothesize that FLVCR
mutations abrogate the known neuro-protective effects of a hemo-
globin-related protein, neuroglobin. However, FLVCR may also serve
to protect these tissues from heme toxicity related to capillary leaks.
5.1.1.2. FLVCR trafﬁcking and localization. Interacting proteins regulate
trafﬁcking of MFS members like FLVCR to and from the plasma
membrane. For example, the glucose transporter-4 (GLUT4) resides in
intracellular storage compartments, but rapidly translocates to the
plasma membrane in response to a signaling cascade initiated by
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discordance between protein expression and mRNA levels [36,37],
while analysis of mammalian FLVCR protein sequences suggests they
contain a PDZ domain-binding motif at the extreme C-terminus, sug-
gesting PDZ domain-containing proteins may regulate FLVCR traf-
ﬁcking and localization. A PDZ domain is a protein structural motif of
80–90aa that helps anchor transmembraneproteins to the cytoskeleton
[192,193]. Using a yeast-two-hybrid screen, we recently identiﬁed a
PDZ domain-containing protein, the nonreceptor protein tyrosine
phosphatase, PTPN3 that interacts with FLVCR. Both proteins co-
immunoprecipitate in cell expression and pull-down assays. Impor-
tantly, their interaction is abolished when either the PDZ domain of
PTPN3 or the 4-aa PDZ-domain bindingmotif of FLVCR is deleted [194].
A role for PTPN3 in anchoring FLVCR to the plasma membrane may
thus have important implications for trafﬁcking and/or membrane
retention of FLVCR in for example, the polarized epithelial cells of the
intestine and kidney.
5.1.1.3. FLVCR-mediated heme export. Heme synthesis (for Hb
production) initiates at the CFU-E/pro-erythroblast stage of erythroid
development [169,170]; thus, a potential role for FLVCR in heme
transport was examined. Using rat kidney epithelial (NRK) cells
overexpressing FLVCR, we demonstrated that FLVCR exports 55Fe-
hemin or zinc mesoporphyrin (ZnMP, a heme analog that also inhibits
HO) over a 90 min washout period, after initial loading [36].
Approximately 50% of the heme taken up by the cells is exported.
Using HPLC methodology, the export rate of exogenously supplied
heme by NRK/FLVCR cells was quantiﬁed as approximately 2-fold that
of control NRK cells (which presumably express the rat ortholog),
provided that HO function is ﬁrst blocked by a short incubation with
ZnMP. In K562 cells, interference with endogenous FLVCR expression
by FeLV-C envelope protein dramatically reduces heme export, to 3%
versus 54% in naive K562 cells. FLVCR-mediated heme export in K562
cells can also be blocked using a polyclonal antibody speciﬁc to FLVCR
(10% export versus 54% in control cells), conﬁrming that cell-surface
FLVCR mediates heme export. The heme export activity of FLVCR has
also been demonstrated using macrophages fromwild-type and Flvcr-
deletedmice [37]. There is no evidence that FLVCR imports heme [36].
Recently, endogenous or exogenously supplied heme was demon-
strated to be the primary physiological substrate for FLVCR. In
addition, under (non-physiological) conditions that increase intracel-
lular PPIX or coproporphyrin levels, FLVCR exports these porphyrins
[38]. However FLVCR does not export unconjugated bilirubin.
Heme export by FLVCR requires an extracellular heme-binding
protein such as albumin or Hpx, as export is not observed in the absence
of a carrier protein [38]. Thus heme may be channeled through FLVCR,
docked at extracellular aminoacid residues, and then released to a heme
carrier protein. By analogy to the bacterial hemophore HasA [195,196],
CssBA [197], and other heme-binding proteins, the residuesHis 145, Tyr
153 andHis 198 of FLVCR are likely to be involved in the heme transport
route and/or heme transfer to extracellular heme-binding proteins
(the common predicted motif is: H-x(7)-Y-x(44)-H, using the Prosite
system[198] pattern syntax; seehttp://ca.expasy.org/tools/scanprosite/
scanprosite-doc.html#pattern_syntax). The histidine residues, con-
served in mammalian FLVCR proteins, but absent in the closely related
paralogs that do not export heme, are predicted to be on extracellular
loops 1 and 2, and thus are optimally located to coordinate heme
docking and export. Recent studies suggest that Hpx – with a similar
arrangement of His residues – functions physiologically to bind heme
that is bound to FLVCR, therefore facilitating for example, the uptake of
heme via FLVCR frommacrophages [38]. Export of heme by NRK/FLVCR
cells is 100-foldmore efﬁcientwhen themedia containsHpx rather than
albumin [38], in keeping with the relative afﬁnities of Hpx and albumin
for heme (Kd b1 pM versus Kd=5 nM; [199,200]). The model is also
supported by the ﬁnding that apo-Hpx directly binds to a 70 aa FLVCR
peptide that encompasses His 145, Tyr 153, and His 198. The in vitrobinding of Hpx to the peptide can be inhibited by incubation of the
(heme-binding) peptide with heme: presumably Hpx removes heme
from the peptide and is then released into the media [38]. Notably, Hpx
is present in high concentration in human serum (6.7–25 μM [201]), a
concentration similar to that of the iron transport protein transferrin
(22–31 μM [202]).
5.1.1.4. FLVCR heme export function in erythropoiesis. As discussed, cats
infected with FeLV-C lack reticulocytes in the circulation and
hemoglobinized cells in the marrow, indicating a block in erythroid
differentiation. Similarly, inducible deletion of its murine receptor,
Flvcr, in one-week-old mice rapidly results in a severe hyperchromic
macrocytic anemia, reticulocytopenia, splenomegaly and a lack of
hemoglobinized cells, again caused by a block in erythropoiesis at the
CFU-E/pro-erythroblast stage, as demonstrated by colony assays or
FACS analysis [37]. In contrast to this purported role for FLVCR in heme
export during early erythropoiesis, previous studies have shown that
exogenous hemepromotes erythroid differentiation of K652 cells and of
the early erythroid progenitor cells, burst-forming units—erythroid
[203–205]. In addition, increasing levels of heme in the nucleus directly
repress a transcriptional repressor of globin genes, Bach1, during
erythropoiesis [8], presumably to allow globin expression for maximal
Hb production. Thus, the requirement for a heme exporter during
erythropoiesis appears counterintuitive.
It is likely however that regulation of potentially toxic heme in
erythroid cells is markedly different from that in non-erythroid cells.
For example, the ﬁrst step in heme synthesis is initiated by erythroid
ALAS2, which is not repressed by increasing heme levels, but rather
regulated by iron supply (see [1]), in contrast to heme repression of
the ubiquitous enzyme ALAS1 in non-erythroid cells [161]. There is
also no evidence to date that HO-1 is induced at this stage of
erythropoiesis—studies, for example, of differentiation of a murine
erythroid (MEL) cell line describe downregulation of HO-1 [206,207].
There is therefore a paucity of mechanisms in erythroid progenitors to
cope with any excess free heme that may occur as heme and then
globin synthesis ramps up. We hypothesize that FLVCR is speciﬁcally
required during this initial phase of heme synthesis, serving as an
overﬂow valve to protect CFU-E/pro-erythroblasts from ﬂuctuating
heme levels and potential heme toxicity until sufﬁcient globin
becomes available to bind heme. In accordance with this hypothesis,
FLVCR expression is downregulated with further erythroid differen-
tiation [36].
Inhibition of FLVCR function during erythroid differentiation of
K562 cells leads to apoptosis, which suggests apoptotic pathway(s)
may be stimulated by direct cellular heme toxicity or as a secondary
effect of impaired erythroid differentiation [36]. It appears that FLVCR,
through rapid modulation of its surface expression by trafﬁcking or
regulatory factors, is well suited to augment regulation of the heme
content of erythroid progenitors, as opposed to the alternative: heme
degradation by induction of HO-1, which, as an enzyme with a long
half-life (~20 h) may prevent optimal erythroid hemoglobinization.
Of interest, a potential imbalance between heme and globin
synthesis during erythropoiesis may be key to a human congenital
form of red cell aplasia, DBA. Mutations of ribosomal proteins (notably
RPS19, 24 and 17) are seen in approximately 45% of patients with DBA
(reviews, [208,209]). Mutation of RPS19 results in defective matura-
tion of the 40S (translation initiation) ribosomal subunit [210],
whereas RPS24 and 17 are also associated with the 40S subunit [202].
These mutations may result in defects in ribosome biogenesis and, in
developing erythroid cells thus delay or decrease initiation of protein,
predominantly globin, translation. Therefore a transient excess in
erythroid progenitor intracellular free heme may occur, analogous to
that predicted for Flvcr-deleted mice where heme export is impaired.
Although a clear link between ribosome biogenesis defects and the
development of the erythroid and myriad non-erythroid tissue
defects seen in DBA is still unclear, Flvcr-null mice embryos do exhibit
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to those observed in patients with DBA—speciﬁcally, ﬂattened faces,
hypertelorism, upper limb and hand/digit abnormalities (see [211]),
suggesting that FLVCR dysfunction and/or heme excess may be
important in the pathogenesis of this disease.
5.1.1.5. FLVCR heme export function in macrophages and systemic iron
homeostasis.Macrophage processing of senescent erythrocytes, ~360 bil-
lion per day [212], generates 25 mg or ~85% of our daily iron re-
quirements. The iron derived from heme catabolism is either exported
by the phagocytic cell-speciﬁc divalentmetal transporter (Nramp1) [213]
and FPN1, or stored as ferritin [214]. But, during erythrocytophagocytosis
not all heme appears to be broken down by HO-1 [215,216], and FLVCR
provides an important heme (iron)-export function that impacts
systemic iron homeostasis [37].When compared to controlmacrophages,
Flvcr-deleted murine macrophages have reduced heme export. Upon
phagocytosis of opsonized erythrocytes they accumulate more ferritin
(from erythroid heme catabolism) than controls; with their ferritin
content increasing further when FPN1-mediated iron export is blocked
by prior incubation with hepcidin [37]. These ﬁndings conﬁrm studies by
Knutson et al. indicating that approximately 25%–30% of heme is re-
exported intact from macrophages following erythrophagocytosis [215].
This fraction may increase during anemia of chronic disease, when
hepcidin levels are high and FPN1 expression is downregulated.
Hpx, a high afﬁnity heme-binding protein, is expressed in the liver,
CNS, retina, skeletal muscle and kidney (review; [217]). It preferen-
tially transports heme in the plasma to CD91-expressing hepatocytes,
where it is subsequently catabolized by heme oxygenases. Hpx
interacts with FLVCR in heme transfer studies and is present in the
circulation at levels similar to that of the iron transporter transferrin
(see above; [38]), suggesting that the systemic circulation of heme
bound to Hpx (or themore abundant plasma protein albumin)may be
of relevance to iron homeostasis. Although it is difﬁcult to ﬁnd
measurements of circulating heme in the literature, a review [201]
indicates the heme-binding capacity of Hpx is approximately 600 μg/
dL (in agreement with an older study [218]), which would contain
approximately 60 μg/dL of iron. In comparison, plasma transferrin-
bound iron lies in a similar range, 50–180 μg/dL. Hpx knockout mice
have been generated [219]; they show no evidence of anemia, with
plasma iron levels and blood parameters (e.g., hematological para-
meters, BR, and albumin) comparable to those of control mice. In
addition there was no evidence of oxidative damage to tissues or
abnormal iron deposits. The lack of a phenotype under physiological
conditions is likely related to transport of circulating heme by albumin,
present in the plasma at a concentration approximately 100 times that
of Hpx (30–55 mg/mL versus 0.5–1 mg/mL). However it may be
possible to dissect the role of systemic heme circulation further in that
the Hpx knockout mouse is available while the heme-binding sites on
albumin are known; in particular, Tyr 138 and Tyr 161 appear critical
[220].
FLVCR is also highly expressed at other potential sites of heme
ﬂux – e.g., in the liver, kidney, duodenum, placenta and uterus – sug-
gesting a role for cell heme export at these sites. Furthermore, inducible
deletion of Flvcr in one-week old mice results in iron overload in
hepatocytes within 5 weeks and subsequently in enterocytes and
splenic macrophages [37], while FLVCR appears to trafﬁc to the apical
membrane of both hepatic and duodenal cells in vitrowhen cellular iron
levels are high.Notably, by7 months there is swellingof thehepatocytes
that line bile canaliculi and biliary stasis, suggesting that heme export
from the liver intobilemay serveas amechanism to ameliorate systemic
iron overload. This mechanism may be especially important for
example, during episodes of hemolysis (likely occurring in Flvcr-deleted
mice) when there is increased heme delivery to the liver. Kappas et al.
found that there was little or no excretion of heme into the biliary
system of rats under physiological circumstances, but infusion of heme
or heat-damaged erythrocytes leads to excretion of small amounts ofbiliary heme (e.g., 14% of the dose of injected heme) [160]. The amount
excreted into the bile increased 3–4-foldwhen Sn-protoporphyrin, a HO
inhibitor, was infused simultaneously with either heme or heat-
damaged erythrocytes, this latter result suggesting that tissue macro-
phages can export heme to hepatocytes when HO function is impaired.
Similar to studies where HO-1−/− BM cells were transplanted into
irradiated HO-1+/+ mice (see Section 3), when Flvcr-deleted BM cells
were transplanted into irradiated Flvcr+/+ mice the transplanted mice
showed no evidence of hepatic iron loading at 5–6 weeks, suggesting
that liver excretion (or, more speculatively, enterocyte secretion [158])
of heme may be important in conditions of heme overload.
A related question is why or under what circumstances cells would
export rather than catabolize heme.We have no clear understanding of
this at present. However, one could speculate that (i) when cells are
overwhelmed by heme and/or iron, for example, when endothelial cells
are exposed to large amounts of heme during intravascular hemolysis,
both pathways are operative; (ii) under hypoxic conditions cells may
preferentially export excess heme, rather than utilizemolecular oxygen
to degrade heme using HO; (iii) as intact heme may also serve as an
intercellular signaling molecule, macrophages may export heme as a
signal of increased erythroid cell turnover; and (iv) more speculatively,
cells may export heme as a form of redox reservoir for adjacent cells.
5.1.1.6. Anopheles FLVCR-like proteins export heme—relevance to
malaria. Hematophagous mosquitoes (females) ingest large amounts
of blood (up to 3× their bodyweight). The responses triggered include
activation of genes for blood digestion, peritrophic matrix formation,
and egg development (vitellogenesis). The rewards are iron (98%
from Hb-heme) and amino acid absorption (60% from Hb-globin),
nutrients critical for vitellogenesis. Hb degradation, however, also
releases large amounts of heme into themosquitomidgut lumen, with
a resultant increase in epithelial exposure to toxic ROS [221–223].
Thus, multiple systems exist to detoxify heme, potentially including
mosquito FLVCR-like transporters that may export heme from the
apical surface of midgut epithelial cells back into the lumen and/or via
the basolateral surfaces into the hemolymph. Using bioinformatics,
orthologs of human Flvcr in the genomes of the most prevalent
malaria transmission vectors, Anopheles gambiae and A. stephensiwere
identiﬁed and cloned. Similar to human FLVCR, overexpression of
these proteins in NRK (or Sf9 (insect)) cells leads to increased export
of ZnMP, which is decreased by treatment of the cells with speciﬁc
siRNA. In addition, mosquito midgut expression of Flvcr mRNA and
protein is upregulated within 24 h of hematophagy, as expected for a
heme exporter during assimilation of a heme load, while confocal
microscopy of midgut cryo-sections reveals epithelial cell-surface
expression of AsFLVCR following a blood meal [224].
Notably, hematophagy represents the major bottleneck for Plasmo-
dium transmission from mosquitoes to humans. Fertilization of P.
falciparum gametocytes in infected ingested blood produces b100
ookinetes in the midgut lumen, with susceptible strains of A. gambiae
killing N80% of them within the midgut [225]. Surviving ookinetes are
susceptible to ROS, and mosquitoes with increased midgut oxidative
stress are resistant to Plasmodium transmission [226]. Recent studies
emphasize the importance of oxidative stress during Plasmodium
ookinete invasion of the mosquito gut epithelium; P. berghei carrying
a deletion of an antioxidant enzyme are arrested at the oocyst stage
[227]. We hypothesize that dysregulation of midgut epithelium FLVCR-
mediated heme export will increase epithelial cell oxidative stress,
potentially impacting Plasmodium transmission at its weakest point.
5.1.2. The role of ABCG2 in cell heme export
The proposed role of themitochondrial transporters ABCB6, ABCB7
and ABCB10 in transport of heme biosynthesis intermediates has been
discussed. Here we review the role of ABCG2/BCRP, a potential cell
surface heme exporter.
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reverse (i.e., NBD is at the N-terminus) half transporter that requires
dimerization to form a functional transporter [228]. It is expressed in
multiple tissues including the intestine, kidney, liver, blood-brain
barrier and placenta, where it can modulate the absorption and
excretion of multiple xenobiotic compounds (reviewed in [229,230]).
It is also expressed in stem cells, including hematopoietic stem cells
[231]. ABCG2 expression is upregulated during erythroid differenti-
ation and the transporter is present on the cell surface of erythrocytes
[232]. Like Flvcr, the Abcg2 promoter region contains consensus GATA-
1 and GATA-2 sites, providing potential mechanisms for upregulation
of the gene during erythroid development.
Knockout mice were generated to investigate the physiological role
of Abcg2 [233,234]. The mice are normal with no apparent phenotypic
(including hematologic) abnormalities. However, knockout mice
serendipitously housed close to a light source while feeding an alfalfa-
containing chow, developed skin photosensitivity with lesions on their
ears, tails, snouts and eye rims [233]. The photosensitivity was traced to
an accumulation of pheophorbide a, a degradation product of
chlorophyll structurally related to PPIX. Compared to wild type mice,
knockoutmice are 100-foldmore photosensitive to orally administered
pheophorbide a, and have 20-fold higher plasma pheophorbide a
levels. Importantly, erythrocytes and the plasma of Bcrp1−/− mice
contain higher levels of PPIX relative to controls, regardless of their diet
[233]. Control murine erythrocytes accumulate similar levels of PPIX
when ABCG2 function is inhibited either by a general decrease in cell
ATP synthesis (using2-deoxy-D-glucose)or by a speciﬁcABCG2 inhibitor,
Ko143. Conversely, K562 cells engineered to overexpress ABCG2 have
decreased retention of exogenously supplied PPIX and an 11-fold
decrease in endogenous PPIX accumulation after ALA treatment. This
increase inPPIXexport is speciﬁcally blockedbyKo143 [232]. Jonker et al.
observed signiﬁcantly increased levels of conjugated PPIX in the
porphyrin-producing harderian gland and liver of Bcrp1−/− mice, with
increased PPIX in the biliary system. They suggest that ABCG2 transports
conjugated PPIX, and has a potential role in murine hepatic excretion
of excess PPIX [235].
A recent report indicates that human ABCG2 exports the heme
analog ZnMP when overexpressed in K562 cells [236], an effect
abrogated by Ko143. Unfortunately only a single (60-minute export)
time point was presented, precluding assessment of initial loading. In
addition, examinationof transport of 55Fe-hemin orHPLC analysis of the
cell media to rigorously demonstrate export [36] was not performed.
Using biophysical methods, the binding of heme to ABCG2 or its large
extracellular loop 3 was demonstrated (Kd 0.2 μM and Kd 0.5–1 μM,
respectively). PPIX, ZnPPIX (present in iron-deﬁcient maturing ery-
throid cells) and pheophorbide a also bind to ABCG2. As albumin can
remove ABCG2-bound hemin, a heme export and transfer mechanism
similar to the mechanism of transfer of heme from FLVCR to Hpx is
proposed [236]. Based on these studies, ABCG2 appears to have
functional redundancy with FLVCR.
Both FLVCR [36,237] and ABCG2 are expressed in hematopoietic
stem cells and erythroid progenitors. However, the Abcg2 knockout
phenotype suggests that ABCG2 heme export function is not critical
during erythropoiesis or for systemic iron homeostasis. ABCG2 has
broad substrate speciﬁcity including xenobiotics, porphyrins, and, as a
recent study indicates, urate [238]. A physiological role for ABCG2 in
heme transport therefore requires further investigation.5.2. Heme importers
Although older studies have suggested the presence of cell-surface
heme importers (e.g., [140]), they have not been identiﬁed to date.
Recently two groups of investigators have used novel approaches in
attempts to identify these proteins in mice and the heme auxotroph,
C. elegans.5.2.1. Proton coupled folate transporter/heme carrier protein 1 (PCFT/HCP1)
Hypotransferrinemic mice have anemia related to low levels of the
iron-binding protein transferrin, which results in low serum iron levels,
repression of hepcidin and a marked increase in intestinal iron
absorption. Since dietary heme represents the most abundant pool of
bio-available iron, it was postulated that heme uptake would also be
increased in this mouse model. Therefore, Shayeghi et al. used a
subtractive RNA hybridization approach on duodenal (the site of
heme import) versus ileal (“zero” heme import) tissues derived from
hypotransferrinemicmice to isolate aputative duodenal heme importer,
heme carrier protein 1 (HCP1, SLC46A1) [139]. The protein (~50 kDa),
like FLVCR, is an MFS member, conserved among species and predicted
to have 12 transmembrane domains [239]. The role of HCP1 in heme/
iron biology [240] was later overshadowed by the ﬁnding that HCP1
primarily functions as an intestinal proton-coupled folate transporter
(PCFT) [241]. Several patients with hereditary familial folate malabsorp-
tion have been identiﬁed as having mutations of the PCFT/HCP1 gene;
one mutation, an exon 3 deletion, was shown to eliminate membrane
localization of the protein and (folate) transport activity [241,242].
Although a consequence of the resultant folate deﬁciency in newborns is
anemia, this is fully corrected by oral doses of 5-formyltetrahydrofolate.
Furthermore, PCFT/HCP1 gene variants are infrequent in hemochroma-
tosis and iron overload screening (HEIRS) study participants [243].
The heme import activity of PCFT/HCP1 was demonstrated in
Xenopus laevis oocytes; injection of PCFT/HCP1 cRNA increases the
uptake of L-arginine-conjugated 55Fe-heme 2.5-fold in a temperature-
dependentmanner. In comparison, PCFT/HCP1-mediated 3H-folic acid
uptakewas 200-fold that of controls, demonstrating PCFT's preference
for folate [241]. Competition studies with an antibody against PCFT/
HCP1 inhibited uptake of both heme and folate, and each substrate
competed with the other to some extent [244]. However, the greater
afﬁnity of PCFT/HCP1 for folate (Km 1 μM) as compared to hemin (Km
N100 μM) suggests that folate is the primary and physiologically more
relevant substrate for this transporter [244,245]. However it should be
mentioned that the concentration of heme in the gastrointestinal tract
following a meal is likely many times higher than that of folate.
Ectopically expressed PCFT/HCP1 in HEK293 cells co-localizes with
Hb:Hp complexes and transferrin in early endosomes, and has thus
been hypothesized to cycle back and forth to the plasma membrane,
possibly due to its di-leucine motif [246]. These investigators
speculate that PCFT/HCP1 functions in endosomes to export heme
released from Hb:Hp into the cytosol for degradation by microsomal
HO. A bona ﬁde physiological role for PCFT/HCP1 in heme metabolism
awaits further clariﬁcation.
5.2.2. Heme responsive genes in Caenorhabditis elegans
The nematode, C. elegans is a heme auxotroph, that is, it lacks
endogenous heme synthesis, depending on environmental heme for
survival, thus providing a “clean” genetic background to study
intracellular heme trafﬁcking pathways. C. elegans has been studied
as a model organism for more than 40 years. The genome has been
sequenced, and many human genes are conserved in C. elegans. In
addition, the ease of genetic manipulation makes it a unique model
system for the identiﬁcation of heme transporters [162,247]. Heme
uptake is a regulated process in C. elegans; when worms are grown in
optimal-to-low heme conditions (b20 μM) and then exposed to
ZnMP, upregulation of heme transporters allows rapid internalization
of ZnMP, however ZnMP uptake is reduced signiﬁcantly when worms
are grown in medium containing 100 μM heme [150]. Hamza's group
performed microarray analyses to identify heme-regulated genes
(hrg) in C. elegans, during growth under low heme (4 μM) versus
optimal (20 μM) versus high heme conditions (500 μM), identifying a
total of 288 genes (now available, [248]). Initially focusing on genes
upregulated in low heme conditions, they further sorted them based
on the predicted presence of transmembrane domains, known trans-
porter function and/or heme- or metal-binding domains. A heme-
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paralogs (hrg-1, hrg-5 and hrg-6)were subjected to further studies [150].
The expression of both hrg-4 and hrg-1 is modulated by the heme
concentration in the growthmedia in contrast to hrg-5 and hrg-6,which
are expressed constitutively. RNAi-based knockdown of CeHRG-4
abolishes uptake of ZnMP in worms grown in low heme, and their
progeny are resistant to feeding with the cytotoxic heme analog gallium
protoporphyrin IX (GaPP). In addition, in voltage clamp experiments on
Xenopus oocytes in the presence of hemin, injection of the Cehrg-4 cRNA
into the oocytes resulted in signiﬁcant inward currents. These ﬁndings
combined with localization studies indicate that CeHRG-4 is a plasma
membrane-associated heme importer, expressed in the worm intestine.
Unfortunately, mammalian orthologs are lacking [150].
In contrast, hrg-1 has orthologs in vertebrates. CeHRG-1 (19 kDa)
has four predicted transmembrane domains and, like FLVCR, contains
predicted YXXØand distal di-leucinemotifs. Thesemotifs lie adjacent to
a C-terminal heme-binding motif. CeHRG-1 knockdown paradoxically
increases ZnMP uptake and does not protect C. elegans from GaPP
toxicity. The human ortholog hHRG-1 is widely expressed, but not
regulated by heme or iron, at least at the transcriptional level. Both
CeHRG-1 and hHRG-1 extensively co-localize with acidic endosome–
lysosome organelles in HEK293 cells, and their afﬁnity for heme
decreases with increasing pH. Xenopus oocyte studies (as above) were
also consistent with heme transport across a membrane. Thus the
available evidence indicates that these proteins transport heme across
the endosome–lysosomes into the cytoplasm. Notably, knockdown of
the zebraﬁsh ortholog results in marked anemia and developmental
defects suggesting the importance of lysosomal heme-recycling from
organelle hemoproteins.
In a more recent study [248], Hamza's group has systematically
knocked down all 288wormgenes in a transgenicworm that responds
to changes in heme levels by altering GFP expression. Genes causing
alterations of ±2-fold were further examined using a cytotoxicity
assay (resistance to GaPP toxicity). In addition to identiﬁcation of
HRG-4, an ABC transporter, MRP-1, which appears to be a cell
membrane permease that exports heme, and F22B5.4, a single TMD
protein of unknown function, were identiﬁed. In sum, their studies
vindicate the use of C. elegans to rapidly identify both cell surface and
cell organelle heme transporters. Further analysis may uncover yet
other heme transporters. Approximately 40% of the 288 worm genes
have orthologs in the human genome and thus it is likely that
vertebrate transporters will also be identiﬁed.
6. Conclusion
There is a large body of literature that supports a seminal role for
the HO system, predominantly HO-1, in protecting cells from
oxidative stress. Although both HO-1 and, to a lesser extent, HO-2
are important for heme–iron reutilization, themurine model of FLVCR
deﬁciency emphasizes the importance of FLVCR-mediated heme
export and heme recycling in systemic iron homeostasis. Future
studies should delineate the importance of systemic heme recycling,
especially in anemia of chronic disease where iron but not heme
export is subject to suppression by hepcidin; the relative contribu-
tions of the HO system and heme export in maintaining intracellular
heme levels; and the physiological conditions whereupon heme
export rather than HO-mediated catabolism occurs.
FLVCR is required during erythropoiesis and likely functions as an
overﬂow valve to mitigate ﬂuctuations in heme levels that may occur
prior to or at the onset of globin synthesis. Investigation of FLVCR
trafﬁcking, protein–protein interactions and internalization/degrada-
tion pathways will yield additional insights into the function and
regulation of this protein.
Of the mammalian ABC transporters, ABCG2 may have functional
redundancy with FLVCR. However, the distinctively different knock-
out mice phenotypes suggest their physiological roles do not overlap.Notably, both proteins are expressed in K562 cells; thus, it would be of
interest to inhibit the function of each in turn and determine their
relative contributions to cell heme export.
PCFT/HCP1 was initially identiﬁed as a duodenal heme importer,
yet subsequent studies indicate that it functions primarily as a folate
transporter; thus, its physiological role in heme acquisition requires
further clariﬁcation. The Pcft knockout mouse has recently been
generated. Although it appears to have signiﬁcant disorders in
homocysteine metabolism related to folate deﬁciency, its potential
role in heme/iron metabolism has not been addressed [249].
Both ABCB6 and ABCB10 are mitochondrial proteins consistently
co-expressed with heme synthesis pathway enzymes, suggesting
roles for these proteins in hememetabolism. A physiological substrate
of ABCB6, relevant to heme synthesis, has yet to be identiﬁed. The last
step of heme synthesis, iron insertion into PPIX by Fech, occurs on the
matrix side of mitochondria, thus indicating the presence of
unidentiﬁed heme exporters on both the mitochondrial IM and OM.
As discussed, ABCB10 physically interacts with Fech and stabilizes
Mfrn1, but it remains to be established whether it has a transport
function (perhaps heme) in addition to its structural role on the
mitochondrial IM.
A recent breakthrough in heme transport biology is the identiﬁ-
cation of HRG proteins in the heme auxotroph C. elegans. HRG-1 and
its human ortholog co-localize to the endosome/lysosome. Further
analysis of HRG proteins in C. elegans [248] and humans [63] will
further our knowledge of heme transport and metabolism.
Increasedunderstanding of cell-surface heme transport proteinswill
provide insights into disease states characterized by the release of free
(toxic) heme, including both congenital and acquired hemolytic
anemias, sickle cell disease, thalassemias, malaria and the myelodys-
plastic syndromes. Fundamental questions in heme physiology remain
unanswered, including the identity of transporters involved in the
transfer of heme and heme intermediates across mitochondrial mem-
branes, the sites of heme transfer to apoproteins to form hemoproteins,
the identity of intracellular heme chaperones, the comparative contribu-
tions of FLVCR and the HO system to cell protection from oxidative
stress and/or heme excess, and the role of systemic circulation of heme in
iron homeostasis and its other functions.
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